Vertex CEO Defends Salary After Company Is Slammed For Orkambi Pricing At UK Hearing
Vertex CEO Jeff Leiden has defended his company’s approach to pricing, as well as his $17m salary, at a heated UK public hearing on access to cystic fibrosis drug Orkambi.
You may also be interested in...
Vertex has managed to secure a deal to provide Scottish cystic fibrosis patients with access to Orkambi and Symkevi. The promise of real world data and a price discount has convinced the Scottish government to say yes to the treatments, which had earlier been rejected by the Scottish Medicines Consortium.
Vertex has come under fire for its alleged extreme rigidity on pricing for its cystic fibrosis drug in England.
European payers and health technology appraisal organizations have warned that their decision making is being increasingly hampered by evidence gaps. Some solutions may lie in the better use of existing mechanisms, such as scientific advice and managed entry agreements, while others could be introduced through the overhaul of the EU pharmaceutical legislation.